Home › NCT07219693

QuantaFlo HD Clinical Validation Study

Who can join

Ages 22 and older · All sexes

Inclusion Criteria:

* Male and female adult (≥ age 22) subjects with a minimum of 1 of the following:
* A history of Cardiovascular Diseasei or PAD
* Recorded history of at least two of the following
* Hypertension
* Diabetes
* Hyperlipidemia

Exclusion Criteria:

* Unable to safely perform a forced expiration, or unable to obtain a technically adequate FE test result
* Subjects with a pacemaker or ICD with pacemaker function
* Terminal advanced illness
* Recent cardiothoracic surgery (within 12 months)
* Retinal eye disease with anticoagulants
* History of eye surgery, within 90 days
* Uncontrolled hypertension \>180 mmHg systolic pressure or \>100 mmHg diastolic pressure
* Subjects with severe tremors

About the study

The primary aim of this validation protocol is to assess cardiovascular function through transthoracic echocardiography ("Echo") measurements and the QuantaFlo HD test measuring blood flow at the finger during a forced expiration ("FE"). The study examines whether Echo-measured GLS values greater than -16% correlate with abnormal responses during FE as measured by QuantaFlo HD.

What is being tested

• QuantaFlo HD (device)

Sponsor: Semler Scientific · Participants: 600 · Started: Aug 21, 2025

Contact the study team

• Gena Parker · Phone: 669-230-2729

Official record on ClinicalTrials.gov — NCT07219693

Locations in the U.S.

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.